Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context
Background: This study aims to evaluate the quality of preclinical data, determine the effect sizes, and identify experimental measures that inform efficacy using mesenchymal stromal (or stem) cells (MSC) therapy in animal models of rheumatoid arthritis (RA). Methods: Literature searches were perfor...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641930595X |
id |
doaj-caedcffb12cf4a08a3ef13578ec437cc |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Linan Liu Chi W. Wong Menglu Han Henry P. Farhoodi Guangyang Liu Yongjun Liu Wenbin Liao Weian Zhao |
spellingShingle |
Linan Liu Chi W. Wong Menglu Han Henry P. Farhoodi Guangyang Liu Yongjun Liu Wenbin Liao Weian Zhao Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context EBioMedicine |
author_facet |
Linan Liu Chi W. Wong Menglu Han Henry P. Farhoodi Guangyang Liu Yongjun Liu Wenbin Liao Weian Zhao |
author_sort |
Linan Liu |
title |
Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context |
title_short |
Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context |
title_full |
Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context |
title_fullStr |
Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context |
title_full_unstemmed |
Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in context |
title_sort |
meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisresearch in context |
publisher |
Elsevier |
series |
EBioMedicine |
issn |
2352-3964 |
publishDate |
2019-09-01 |
description |
Background: This study aims to evaluate the quality of preclinical data, determine the effect sizes, and identify experimental measures that inform efficacy using mesenchymal stromal (or stem) cells (MSC) therapy in animal models of rheumatoid arthritis (RA). Methods: Literature searches were performed on MSC preclinical studies to treat RA. MSC treatment effect sizes were determined by the most commonly used outcome measures, including paw thickness, clinical score, and histological score. Findings: A total of 48 studies and 94 treatment arms were included, among which 42 studies and 79 treatment arms reported that MSC improved outcomes. The effect sizes of RA treatments using MSC, when compared to the controls, were: paw thickness was ameliorated by 53.6% (95% confidence interval (CI): 26.7% −80.4%), histological score was decreased by 44.9% (95% CI: 33.3% −56.6%), and clinical score was decreased by 29.9% (95% CI: 16.7% −43.0%). Specifically, our results indicated that human umbilical cord derived MSC led to large improvements of the clinical score (−42.1%) and histological score (−51.4%). Interpretation: To the best of our knowledge, this meta-analysis is to quantitatively answer whether MSC represent a robust RA treatment in animal models. It suggests that in preclinical studies, MSC have consistently exhibited therapeutic benefits. The findings demonstrate a need for considering variations in different animal models and treatment protocols in future studies using MSC to treat RA in humans to maximise the therapeutic gains in the era of precision medicine. Funds: NIH [1DP2CA195763], Baylx Inc.: BI-206512, NINDS/NIH Training Grant [Award# NS082174]. Keywords: Mesenchymal stromal (or stem) cells, MSC, Rheumatoid arthritis, Pre-clinical study, Clinical trials, Meta-analysis |
url |
http://www.sciencedirect.com/science/article/pii/S235239641930595X |
work_keys_str_mv |
AT linanliu metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT chiwwong metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT mengluhan metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT henrypfarhoodi metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT guangyangliu metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT yongjunliu metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT wenbinliao metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext AT weianzhao metaanalysisofpreclinicalstudiesofmesenchymalstromalcellstotreatrheumatoidarthritisresearchincontext |
_version_ |
1724956750878081024 |
spelling |
doaj-caedcffb12cf4a08a3ef13578ec437cc2020-11-25T02:01:36ZengElsevierEBioMedicine2352-39642019-09-0147563577Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritisResearch in contextLinan Liu0Chi W. Wong1Menglu Han2Henry P. Farhoodi3Guangyang Liu4Yongjun Liu5Wenbin Liao6Weian Zhao7Sue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USASue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USASue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USASue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USASue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Surgery, University of California-Irvine, Irvine, CA 92697, USASue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USABaylx, Inc., 1 Technology Dr, C511, Irvine, CA 92618, USA; Corresponding authors at: Sue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA.Sue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA; Department of Pharmaceutical Sciences, University of California-Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA 92697, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California-Irvine, Irvine, CA 92697, USA; Departments of Biomedical Engineering and Biological Chemistry, University of California-Irvine, Irvine, CA 92697, USA; Corresponding authors at: Sue and Bill Gross Stem Cell Research Center, 845 Health Sciences Road, University of California-Irvine, Irvine, CA 92697, USA.Background: This study aims to evaluate the quality of preclinical data, determine the effect sizes, and identify experimental measures that inform efficacy using mesenchymal stromal (or stem) cells (MSC) therapy in animal models of rheumatoid arthritis (RA). Methods: Literature searches were performed on MSC preclinical studies to treat RA. MSC treatment effect sizes were determined by the most commonly used outcome measures, including paw thickness, clinical score, and histological score. Findings: A total of 48 studies and 94 treatment arms were included, among which 42 studies and 79 treatment arms reported that MSC improved outcomes. The effect sizes of RA treatments using MSC, when compared to the controls, were: paw thickness was ameliorated by 53.6% (95% confidence interval (CI): 26.7% −80.4%), histological score was decreased by 44.9% (95% CI: 33.3% −56.6%), and clinical score was decreased by 29.9% (95% CI: 16.7% −43.0%). Specifically, our results indicated that human umbilical cord derived MSC led to large improvements of the clinical score (−42.1%) and histological score (−51.4%). Interpretation: To the best of our knowledge, this meta-analysis is to quantitatively answer whether MSC represent a robust RA treatment in animal models. It suggests that in preclinical studies, MSC have consistently exhibited therapeutic benefits. The findings demonstrate a need for considering variations in different animal models and treatment protocols in future studies using MSC to treat RA in humans to maximise the therapeutic gains in the era of precision medicine. Funds: NIH [1DP2CA195763], Baylx Inc.: BI-206512, NINDS/NIH Training Grant [Award# NS082174]. Keywords: Mesenchymal stromal (or stem) cells, MSC, Rheumatoid arthritis, Pre-clinical study, Clinical trials, Meta-analysishttp://www.sciencedirect.com/science/article/pii/S235239641930595X |